Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted therapy.

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.

A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially benefit from shorter or less-intensive treatment.